8i50
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | + | ==Crystal structure of DNA octamer containing GuNA[Me,Me]== | |
| + | <StructureSection load='8i50' size='340' side='right'caption='[[8i50]], [[Resolution|resolution]] 0.95Å' scene=''> | ||
| + | == Structural highlights == | ||
| + | <table><tr><td colspan='2'>[[8i50]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Synthetic_construct Synthetic construct]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8I50 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=8I50 FirstGlance]. <br> | ||
| + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 0.95Å</td></tr> | ||
| + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=BRU:5-BROMO-2-DEOXYURIDINE-5-MONOPHOSPHATE'>BRU</scene>, <scene name='pdbligand=OIQ:[(1R,3R,4R,7S)-5-[(E)-N,N-dimethylcarbamimidoyl]-3-[5-methyl-2,4-bis(oxidanylidene)pyrimidin-1-yl]-7-oxidanyl-2-oxa-5-azabicyclo[2.2.1]heptan-1-yl]methyl+dihydrogen+phosphate'>OIQ</scene></td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8i50 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8i50 OCA], [https://pdbe.org/8i50 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8i50 RCSB], [https://www.ebi.ac.uk/pdbsum/8i50 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8i50 ProSAT]</span></td></tr> | ||
| + | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Antisense oligonucleotides (ASOs) are becoming a promising class of drugs for treating various diseases. Over the past few decades, many modified nucleic acids have been developed for application to ASOs, aiming to enhance their duplex-forming ability toward cognate mRNA and improve their stability against enzymatic degradations. Modulating the sugar conformation of nucleic acids by substituting an electron-withdrawing group at the 2'-position or incorporating a 2',4'-bridging structure is a common approach for enhancing duplex-forming ability. Here, we report on incorporating an N-tert-butylguanidinium group at the 2',4'-bridging structure, which greatly enhances duplex-forming ability because of its interactions with the minor groove. Our results indicated that hydrophobic substituents fitting the grooves of duplexes also have great potential to increase duplex-forming ability. | ||
| - | + | Mechanism of the extremely high duplex-forming ability of oligonucleotides modified with N-tert-butylguanidine- or N-tert-butyl-N'-methylguanidine-bridged nucleic acids.,Yamaguchi T, Horie N, Aoyama H, Kumagai S, Obika S Nucleic Acids Res. 2023 Jul 18:gkad608. doi: 10.1093/nar/gkad608. PMID:37462081<ref>PMID:37462081</ref> | |
| - | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
| - | [[Category: | + | </div> |
| - | [[Category: Aoyama | + | <div class="pdbe-citations 8i50" style="background-color:#fffaf0;"></div> |
| - | [[Category: Obika | + | == References == |
| - | [[Category: Yamaguchi | + | <references/> |
| + | __TOC__ | ||
| + | </StructureSection> | ||
| + | [[Category: Large Structures]] | ||
| + | [[Category: Synthetic construct]] | ||
| + | [[Category: Aoyama H]] | ||
| + | [[Category: Obika S]] | ||
| + | [[Category: Yamaguchi T]] | ||
Current revision
Crystal structure of DNA octamer containing GuNA[Me,Me]
| |||||||||||
